🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

French National MICMAF Cohort

Recruitingn/aAges 18 Years - 75 YearsAllAssistance Publique - Hôpitaux de Paris
NCT05895890 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Excessive alcohol consumption is a major public health problem, particularly in France. It is the leading cause of cirrhosis and hepatocellular carcinoma. Among subjects with heavy alcohol consumption, the majority of patients develop fatty liver overload (steatosis), but only 10 to 35% develop acute alcoholic hepatitis (AAH) and 8 to 20% progress to cirrhosis. Steatosis is the earliest lesion, rapidly reversible after abstinence from alcohol. On the other hand, the occurrence of AAH leads to a strong progression of fibrosis. The investigators have shown on serial liver biopsies that a subgroup of heavy drinkers develop episodes of AAH and progress to cirrhosis. Therefore, factors other than the amount of alcohol consumed alone influence the development and progression of alcoholic liver disease (ALD). Among these factors, it is now accepted that the gut microbiome plays an important rol

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 18 and 75 years * Average alcohol consumption of more than 20 g per day in women and 30 g per day in men during the previous year; * Patients seen in consultation or hospitalized for assessment of alcoholic liver disease and management of alcohol addiction; * Having given their consent to participate in this study; * Affiliated to a social security system (beneficiary or beneficiary's right). Exclusion Criteria: * Antibiotic, probiotic or prebiotic treatment within the previous 3 months ; * Digestive hemorrhage, acute pancreatitis, acute or chronic diarrhea (except diarrhea related to excessive alcohol consumption) or chronic inflammatory bowel disease; * Another cause of liver damage; * A serious associated pathology (respiratory failure, heart failure, severe psychiatric disorders, active cancer). * Patient under guardianship or curatorship
💊

What it tests

  • Sequential sampling (stool, saliva, serum) .
📍

Where

1 site
Cosmin Voican
Clamart, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy